Friday, 2 January 2015

Global Lonsurf (Colorectal Cancer) – Forecast, Size, Trends and Market Analysis to 2023

Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with your industry research requirements or email the details on sales@researchmoz.us

Summary


GlobalData has released its new PharmaPoint Drug Evaluation report, Lonsurf (Colorectal Cancer) - Forecast and Market Analysis to 2023. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems.

To Browse a Full Report with Toc
: http://www.researchmoz.us/lonsurf-colorectal-cancer-forecast-and-market-analysis-to-2023-report.html

This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

Scope

- Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Lonsurf including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Lonsurf for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Reasons to buy


- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Lonsurf performance
- Obtain sales forecast for Lonsurf from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 13
3.2 Clinical Staging 14
3.3 Symptoms 15
4 Disease Management 17
4.1 Diagnosis and Treatment Overview 17
4.1.1 Screening and Diagnosis 17

1.1 List of Tables
Table 1: TNM and Staging Classification System for CRC 15
Table 2: Symptoms of Colorectal Cancer 16
Table 3: Treatment Guidelines for CRC 21
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013 22
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013 23
Table 6: Leading Treatments for CRC, 2014 32
Table 7: Product Profile - Lonsurf 35
Table 8: Lonsurf SWOT Analysis, 2014 37
Table 9: Global Sales Forecasts ($m) for Lonsurf (TAS-102), 2013-2023 38
Table 10: Average Body Weight and Surface Area Across the 8MM 49
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 53

To Browse a Full Report with Toc: http://www.researchmoz.us/lonsurf-colorectal-cancer-forecast-and-market-analysis-to-2023-report.html

All Reports of this Category Here: http://www.researchmoz.us/pharmaceutical-market-reports-38.html


About ResearchMoz


ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Contact US:


For More Information Kindly Contact:
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Blog: http://mresearchreports.blogspot.com/
Get More Market Research Report : https://www.linkedin.com/today/author/355409463

Global MGN1703 (Colorectal Cancer) - Forecast and Market Analysis to 2023

Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with your industry research requirements or email the details on sales@researchmoz.us

Summary


GlobalData has released its new PharmaPoint Drug Evaluation report, MGN1703 (Colorectal Cancer) - Forecast and Market Analysis to 2023. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems.

To Browse a Full Report with Toc
: http://www.researchmoz.us/mgn1703-colorectal-cancer-forecast-and-market-analysis-to-2023-report.html

This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

Scope


- Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on MGN1703 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for MGN1703 for the top five countries from 2013 to 2023.
- Sales information covered for France, Germany, Italy, Spain and the UK.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of MGN1703 performance
- Obtain sales forecast for MGN1703 from 2013-2023 in top five countries (France, Germany, Italy, Spain and the UK).

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Clinical Staging 15

1.1 List of Tables
Table 1: TNM and Staging Classification System for CRC 16
Table 2: Symptoms of Colorectal Cancer 17
Table 3: Treatment Guidelines for CRC 22
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013 23
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013 24
Table 6: Leading Treatments for CRC, 2014 33
Table 7: Unmet Need and Opportunity in CRC 35
Table 8: Product Profile - MGN1703 50
Table 9: MGN1703 SWOT Analysis, 2014 53
Table 10: Global Sales Forecasts ($m) for MGN1703, 2013-2023 54
Table 11: Average Body Weight and Surface Area Across the 8MM 67
Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 69

To Browse a Full Report with Toc: http://www.researchmoz.us/mgn1703-colorectal-cancer-forecast-and-market-analysis-to-2023-report.html

All Reports of this Category Here: http://www.researchmoz.us/pharmaceutical-market-reports-38.html

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Contact US:


For More Information Kindly Contact:
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Blog: http://mresearchreports.blogspot.com/
Get More Market Research Report : https://www.linkedin.com/today/author/355409463

Global Nintedanib (Colorectal Cancer) – Size, Trends, Forecast and Market Analysis to 2023

Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with your industry research requirements or email the details on sales@researchmoz.us

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Nintedanib (Colorectal Cancer) - Forecast and Market Analysis to 2023. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems.

To Browse a Full Report with Toc:
http://www.researchmoz.us/nintedanib-colorectal-cancer-forecast-and-market-analysis-to-2023-report.html

This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

Scope

- Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Nintedanib including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Nintedanib for the top seven countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Nintedanib performance
- Obtain sales forecast for Nintedanib from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Clinical Staging 15
3.3 Symptoms 16
4 Disease Management 18

1.1 List of Tables
Table 1: TNM and Staging Classification System for CRC 16
Table 2: Symptoms of Colorectal Cancer 17
Table 3: Treatment Guidelines for CRC 22
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013 23
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013 24
Table 6: Leading Treatments for CRC, 2014 33
Table 7: Unmet Need and Opportunity in CRC 35
Table 8: Product Profile - Nintedanib 49
Table 9: Nintedanib SWOT Analysis, 2014 51
Table 10: Global Sales Forecasts ($m) for Nintedanib, 2013-2023 51
Table 11: Average Body Weight and Surface Area Across the 8MM 63
Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 66

1.2 List of Figures
Figure 1: CRC - Phase III Pipeline 46
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in CRC, 2013-2023 47
Figure 3: Clinical and Commercial Positioning of Nintedanib 50

To Browse a Full Report with Toc: http://www.researchmoz.us/nintedanib-colorectal-cancer-forecast-and-market-analysis-to-2023-report.html

All Reports of this Category Here: http://www.researchmoz.us/pharmaceutical-market-reports-38.html


About ResearchMoz


ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Contact US:


For More Information Kindly Contact:
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Blog: http://mresearchreports.blogspot.com/
Get More Market Research Report : https://www.linkedin.com/today/author/355409463

Global Stivarga (Colorectal Cancer) - Forecast and Market Analysis to 2023

Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with your industry research requirements or email the details on sales@researchmoz.us

Summary


GlobalData has released its new PharmaPoint Drug Evaluation report, Stivarga (Colorectal Cancer) - Forecast and Market Analysis to 2023. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems.

To Browse a Full Report with Toc: http://www.researchmoz.us/stivarga-colorectal-cancer-forecast-and-market-analysis-to-2023-report.html

This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

Scope

- Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Stivarga including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Stivarga for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Stivarga performance
- Obtain sales forecast for Stivarga from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK,Japan and China)

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Clinical Staging 15
3.3 Symptoms 16
4 Disease Management 18
4.1 Diagnosis and Treatment Overview 18
4.1.1 Screening and Diagnosis 18
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 21
4.1.3 Clinical Practice 25
5 Competitive Assessment 32
5.1 Overview 32

1.1 List of Tables
Table 1: TNM and Staging Classification System for CRC 16
Table 2: Symptoms of Colorectal Cancer 17
Table 3: Treatment Guidelines for CRC 22
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013 23
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013 24
Table 6: Leading Treatments for CRC, 2014 33
Table 7: Product Profile - Stivarga 36
Table 8: Stivarga SWOT Analysis, 2014 37
Table 9: Global Sales Forecasts ($m) for Stivarga, 2013-2023 38
Table 10: Average Body Weight and Surface Area Across the 8MM 49
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 52

To Browse a Full Report with Toc: http://www.researchmoz.us/stivarga-colorectal-cancer-forecast-and-market-analysis-to-2023-report.html

All Reports of this Category Here: http://www.researchmoz.us/pharmaceutical-market-reports-38.html

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Contact US:


For More Information Kindly Contact:
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Blog: http://mresearchreports.blogspot.com/
Get More Market Research Report : https://www.linkedin.com/today/author/355409463

Global TS-1 (Colorectal Cancer) - Forecast and Market Analysis to 2023

Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with your industry research requirements or email the details on sales@researchmoz.us

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, TS-1 (Colorectal Cancer) - Forecast and Market Analysis to 2023. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems.

 To Browse a Full Report with Toc: http://www.researchmoz.us/ts-1-colorectal-cancer-forecast-and-market-analysis-to-2023-report.html

This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

Scope


- Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on TS-1 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for TS-1 for the top country from 2013 to 2023.
- Sales information covered for Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of TS-1 performance
- Obtain sales forecast for TS-1 from 2013-2023 in top country (Japan)

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Clinical Staging 15
3.3 Symptoms 16

1.1 List of Tables
Table 1: TNM and Staging Classification System for CRC 16
Table 2: Symptoms of Colorectal Cancer 17
Table 3: Treatment Guidelines for CRC 22
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013 23
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013 24
Table 6: Leading Treatments for CRC, 2014 33
Table 7: Product Profile - TS-1 35
Table 8: TS-1 SWOT Analysis, 2014 36
Table 9: Global Sales Forecasts ($m) for TS-1, 2013-2023 37
Table 10: Average Body Weight and Surface Area Across the 8MM 48
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 52

To Browse a Full Report with Toc: http://www.researchmoz.us/ts-1-colorectal-cancer-forecast-and-market-analysis-to-2023-report.html

All Reports of this Category Here: http://www.researchmoz.us/pharmaceutical-market-reports-38.html


About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Contact US:


For More Information Kindly Contact:
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Blog: http://mresearchreports.blogspot.com/
Get More Market Research Report : https://www.linkedin.com/today/author/355409463

Global Zaltrap (Colorectal Cancer) - Forecast and Market Analysis to 2023

Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with your industry research requirements or email the details on sales@researchmoz.us

Summary


GlobalData has released its new PharmaPoint Drug Evaluation report, Zaltrap (Colorectal Cancer) - Forecast and Market Analysis to 2023. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems.

To Browse a Full Report with Toc: http://www.researchmoz.us/zaltrap-colorectal-cancer-forecast-and-market-analysis-to-2023-report.html

This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

Scope


- Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Zaltrap including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Zaltrap for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK Japan, and China.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Zaltrap performance
- Obtain sales forecast for Zaltrap from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK Japan, and China)

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Clinical Staging 15
3.3 Symptoms 16
4 Disease Management 18
4.1 Diagnosis and Treatment Overview 18
4.1.1 Screening and Diagnosis 18
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 21

1.1 List of Tables
Table 1: TNM and Staging Classification System for CRC 16
Table 2: Symptoms of Colorectal Cancer 17
Table 3: Treatment Guidelines for CRC 22
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013 23
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013 24
Table 6: Leading Treatments for CRC, 2014 33
Table 7: Product Profile - Zaltrap 35
Table 8: Zaltrap SWOT Analysis, 2014 37
Table 9: Global Sales Forecasts ($m) for Zaltrap, 2013-2023 38
Table 10: Average Body Weight and Surface Area Across the 8MM 49
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 53

To Browse a Full Report with Toc:
http://www.researchmoz.us/zaltrap-colorectal-cancer-forecast-and-market-analysis-to-2023-report.html

All Reports of this Category Here: http://www.researchmoz.us/pharmaceutical-market-reports-38.html

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Contact US:

For More Information Kindly Contact:
Email: sales@researchmoz.usWebsite @ http://www.researchmoz.us/
Blog: http://mresearchreports.blogspot.com/
Get More Market Research Report : https://www.linkedin.com/today/author/355409463

Pharma Point Colorectal Cancer Current and Future Players

Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with your industry research requirements or email the details on sales@researchmoz.us

Summary

GlobalData has released its pharma report, PharmaPoint: Colorectal Cancer - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Colorectal Cancer Market.

To Browse a Full Report with Toc: http://www.researchmoz.us/pharmapoint-colorectal-cancer-current-and-future-players-report.html

The report identifies and analyses the key companies shaping and driving the global Colorectal Cancer market. The report provides insight into the competitive Colorectal Cancer landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalDatas team of industry experts.

Scope

- Investigation of current and future market competition for Colorectal Cancer
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of Colorectal Cancer sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving Colorectal Cancer market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- Whats the next big thing in the global Colorectal Cancer market landscape? Identify, understand and capitalize

1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 9
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
2.3 Upcoming Related Reports 13
3 Market Outlook 14
3.1 Global Markets 14
3.1.1 Forecast 14
3.1.2 Drivers and Barriers - Global Issues 18
4 Current and Future Players 21
4.1 Overview 21

1.1 List of Tables
Table 1: Sales Forecasts ($m) for Colorectal Cancer in the Global Markets, 2013-2023 16
Table 2: CRC Market Drivers and Barriers, 2014 18
Table 3: Key Companies in the CRC Market in the 8MM, 2013-2023 23
Table 4: Roches CRC Portfolio Assessment, 2014 28
Table 5: Sanofis CRC Portfolio Assessment, 2014 31
Table 6: Eli Lillys CRC Portfolio Assessment, 2014 34
Table 7: Merck KGaAs CRC Portfolio Assessment, 2014 37
Table 8: Bayers CRC Portfolio Assessment, 2014 40
Table 9: Taihos CRC Portfolio Assessment, 2014 43
Table 10: Average Body Weight and Surface Area Across the 8MM 53
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 55

1.2 List of Figures
Figure 1: Global Sales for Colorectal Cancer by Region, 2013-2023 17
Figure 2: Global Sales of Branded Products for Colorectal Cancer by Company, 2013-2023 24
Figure 3: Company Portfolio Gap Analysis in CRC, 2013-2023 25
Figure 4: Roche SWOT Analysis in CRC, 2014 29
Figure 5: Sanofi SWOT Analysis in CRC, 2014 32
Figure 6: Eli Lilly SWOT Analysis in CRC, 2014 35
Figure 7: Merck KGaA SWOT Analysis in CRC, 2014 38
Figure 8: Bayer SWOT Analysis in CRC, 2014 41
Figure 9: Taiho SWOT Analysis in CRC, 2014 44

To Browse a Full Report with Toc:
http://www.researchmoz.us/pharmapoint-colorectal-cancer-current-and-future-players-report.html

All Reports of this Category Here: http://www.researchmoz.us/pharmaceutical-market-reports-38.html


About ResearchMoz


ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Contact US:

For More Information Kindly Contact:
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Blog: http://mresearchreports.blogspot.com/
Get More Market Research Report : https://www.linkedin.com/today/author/355409463